Results 231 to 240 of about 21,287,561 (278)

Plasminogen Activator Inhibitor‐1 is Internalized by Endothelial Cells via A Pinocytosis‐Like Mechanism and Evades Degradation

The FASEB Journal, Volume 40, Issue 10, 31 May 2026.
Plasminogen activator inhibitor 1 (PAI1) is a secreted protein that also regulates intracellular processes, such as inhibition of endothelial nitric oxide synthase (eNOS). Interaction between Plasminogen Activators (PA) and PAI1 results in a covalent linkage.
Molly McAdow, Gjina Ahmetaj, Rachel Hauschel, Anne Eichmann, William Sessa   +4 more
wiley   +1 more source

The Relationship Between Vascular Endothelial Growth Factor Expression in T Cell Subsets and Survival of Patients With Colorectal Cancer. [PDF]

Cancer Diagn Progn
Artaç M, Ceylan A, Yildiz O, Saçkan F, Eryilmaz MK, Araz M, Artaç H, Emiroğlu M.   +7 more
europepmc   +1 more source

New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: <i>in silico</i> study, synthesis, and cytotoxicity evaluation. [PDF]

Res Pharm Sci
Abdulhussein AN, Oleiwi MA.
europepmc   +1 more source

In Silico Studies of Potent Tyrosine Kinase Inhibitors: Molecular Docking and Pharmacophore Modeling Approaches. [PDF]

Molecules
Mavridis E, Pontiki E, Hadjipavlou-Litina D.   +2 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

The anti-angiogenic and anti-proliferative activity of n-benzoyl-3-phenyl isoserine derivative containing 1,2,3-triazole and quinoline rings. [PDF]

PLoS One
Hussein NR, Sahib HB, Omran ZS.
europepmc   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Ramucirumab induces apoptosis in Caco-2 cells via mitochondrial impairment and caspase activation. [PDF]

Saudi Pharm J
Al-Dogmi AM, Al-Anazi KM, Qamar W, Farah MA.   +3 more
europepmc   +1 more source

Novel Pyrrolopyridazine Compounds as VEGFR Inhibitors for Treating Cancer. [PDF]

ACS Med Chem Lett
Sabnis RW.
europepmc   +1 more source

Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. [PDF]

Hypertension
Ky B, Liu T, Margulies KB, Mitchell JD, Haas NB, Gareen IF, Thangarajah M, Sicks JD, Domenico C, Narayan VK, Smith AM, Wilcox NS, Mittal K, Rhee JW, Armenian SH, Saphner T, Paul AK, Gartrell BA, Zaha VG, Anari F, Wong RL, Townsend RR, Wagner LI.   +22 more
europepmc   +1 more source